Olopatadină Rompharm (Olopatadine)

Olopatadine blocks histamine H1 receptors on mast cells in the eye, preventing histamine‑induced vasodilation and vascular leakage. It also stabilises mast cells, reducing the release of other inflammatory mediators, which together diminish itching, redness, and swelling.

The specific dose and frequency are determined by the prescribing clinician based on the patient’s age, severity of symptoms, and formulation (eye drops or oral tablets). Patients should follow the prescriber’s instructions and the product label.

Safety data are limited. Women who are pregnant or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Olopatadină Rompharm. The prescriber will decide if the medication is appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Olopatadine offers both H1‑receptor antagonism and mast‑cell stabilisation, providing rapid symptom relief and longer‑lasting control compared with many first‑generation antihistamine drops that lack mast‑cell stabilising activity. Clinical choice depends on efficacy, tolerability and patient preference.

Store Olopatadină Rompharm at room temperature, below 25 °C, in the original packaging. Protect the container from direct sunlight, moisture and extreme temperature fluctuations to maintain product stability.

For the ophthalmic solution, instil the prescribed number of drops into the affected eye(s) as directed, typically once or twice daily. If an oral formulation is supplied, the tablet should be swallowed with water according to the prescriber’s instructions.

Serious adverse events, though rare, include corneal edema, severe allergic reactions such as anaphylaxis, and increased intra‑ocular pressure. Patients should seek immediate medical attention if they experience sudden vision changes, severe eye pain, or signs of systemic hypersensitivity.

Individuals with a known hypersensitivity to olopatadine or any excipients in the formulation should avoid the product. Caution is also advised for patients with uncontrolled glaucoma, severe ocular infections, or those who cannot safely remove contact lenses before administration.